Floatz logo

10 assets in Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication

Therapeutic assets addressing Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Gilteritinib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
The First Affiliated Hospital of Soochow UniversityP3BB (69)
Azacitidine
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
French Innovative Leukemia OrganisationP2BB (66)
Cytarabine
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
First Affiliated Hospital of Zhejiang UniversityP3BB (66)
Sorafenib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
The First Affiliated Hospital of Soochow UniversityP3BB (65)
xy0206
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Shijiazhuang Yiling Pharmaceutical Co. LtdP3BB (64)
Venetoclax
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
First Affiliated Hospital of Zhejiang UniversityP2B (60)
Moxifloxacin
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Shijiazhuang Yiling Pharmaceutical Co. LtdP1CC (43)
Nintedanib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Northwestern UniversityP1CC (43)
Revumenib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Uma BorateP1CC (43)
Vyxeos
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
H. Lee Moffitt Cancer Center and Research InstituteP1CC (43)